Targeted Therapies Continue to Evolve in Metastatic NSCLC
Published: Monday, Dec 02, 2019
Kathryn C. Arbour, MD
The proliferation of targeted therapies in non–small cell lung cancer (NSCLC) has helped improve overall survival (OS) for patients with metastatic disease and illustrates the importance of molecular testing, according to a recent analysis published in JAMA.
... to read the full story